Preparation method and application of Janus nano-drug carrier for enhancing generation of active oxygen

By growing the Cu-MOF layer on the side of Prussian blue and loading the antibacterial drug berberine, Janus nanodrug carrier was prepared, which solved the problem of insufficient reactive oxygen generation capacity of Prussian blue, and achieved chemical kinetics and photothermal antibacterial therapy. Improves the bioavailability and therapeutic efficiency of drugs.

CN118987203APending Publication Date: 2024-11-22NORTHEAST FORESTRY UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410777987.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing Prussian blue materials have weak reactive oxygen generation ability, single function, and low bioavailability of antibacterial drugs, which limits their application in antibacterial therapy.

Method used

Using the preparation method of Janus nanomedicine carrier, the Cu-MOF layer is grown on the side of Prussian blue, and the coordination effect of polyacrylic acid and copper ions is used to improve the ability of H2O2 to convert into highly toxic hydroxyl radicals, and enhance it through photothermal therapy. Antibacterial effect, while physically loading the antibacterial drug berberine, achieving chemical kinetics and photothermal combined antibacterial treatment.

Benefits of technology

It significantly improves the reactive oxygen generation ability, enhances the antibacterial effect, and achieves the drug sustained release and coordinated treatment through berberine loaded with antibacterial drugs, improving the bioavailability and treatment efficiency of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987203A_ABST
    Figure CN118987203A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of a Janus nano-drug carrier for enhancing generation of active oxygen, and relates to a preparation method and application of a Janus nano-drug carrier. The invention aims to solve the problems that the existing PB material is relatively weak in active oxygen generation capability, single in function and low in bioavailability of antibacterial drugs. The method comprises the following steps: 1, preparing Prussian blue PB; 2, preparing a Janus nano-drug carrier; according to the application, the material is used for chemical kinetic therapy, photo-thermal therapy and drug loading; the medicine is an antibacterial medicine or an anti-cancer medicine. The invention relates to preparation and application of a Janus nano-drug carrier for enhancing active oxygen generation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a preparation method and application of a Janus nano drug carrier. Background Art

[0002] Bacterial infection is an increasingly serious public health challenge today. The widespread use of antibiotics has greatly reduced the morbidity and mortality of bacterial infections. However, due to the biological characteristics of bacteria themselves and the abuse of antibiotics, many bacteria have developed varying degrees of resistance to currently known antibiotics, making the treatment of bacterial infections increasingly challenging. Natural plant medicines have attracted much attention due to their powerful antibacterial activity and were widely used in the treatment of bacterial infections before the advent of antibiotics. Compared with synthetic compounds such as antibiotics, natural plant medicines have higher biosafety, good antibacterial effects on common bacteria, and also show significant inhibitory effects on certain resistant strains. However, many natural plant medicines have poor water solubility and low bioavailability, which prevents them from effectively exerting their antibacterial effects at the site of infection.

[0003] With the continuous advancement of nanomedicine technology, the use of nano drug carriers has attracted widespread attention. These carriers not only have the ability to accurately deliver drugs to the lesion site and improve the bioavailability of drugs, but also can build a multifunctional treatment platform, using the inherent properties of the carrier or loading corresponding functional drugs to achieve a combination of chemodynamic therapy, photothermal therapy and other treatment methods. For example, nano drug carriers can act as catalysts for Fenton-like reactions, converting H in the infected microenvironment to 2 O 2 Catalytic conversion into toxic reactive oxygen species (ROS) to achieve chemodynamic therapy (CDT); at the same time, nano drug carriers can also act as photothermal agents (PTA), converting light energy into thermal energy under the irradiation of a light source of a specific wavelength, leading to bacterial membrane rupture, protein denaturation and irreversible bacterial damage, thereby achieving a broad-spectrum antibacterial photothermal therapy (PTT) effect. Therefore, designing nano drug carriers that can mediate the joint antibacterial effects of multiple treatments to achieve drug delivery and joint antibacterial effects of multiple treatments is of great significance for antibacterial therapy.

[0004] Prussian blue (PB), molecular formula is Fe 4 [Fe(CN) 6 ] 3 ·nH 2 O, is a prototype of microporous coordination polymer / metal-organic framework. The study found that Fe 2+ , Fe 3+ and cyanide ions alternately coordinate to form a cubic unit cell, Fe 2+ and Fe 3+By transferring electrons through the cyanide group, PB can catalyze hydrogen peroxide (H2O2) in a weakly acidic infection microenvironment through a Fenton-like reaction. 2 O 2 ) generates hydroxyl radicals (·OH). However, due to Fe 2+ to Fe 3+ The low conversion rate results in its weak reactive oxygen generation ability, and its single function leads to low bioavailability of antibacterial drugs, which in turn limits its practical application. Summary of the invention

[0005] The present invention aims to solve the problems of weak active oxygen generation ability, single function and low bioavailability of antibacterial drugs in existing PB materials, and further provide a preparation method and application of a Janus nano drug carrier for enhancing active oxygen generation.

[0006] A method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen is carried out according to the following steps:

[0007] 1. Preparation of Prussian Blue PB:

[0008] ① Adjust the pH of deionized water to 1-1.5 to obtain a solvent;

[0009] ② At room temperature, K 3 [Fe(CN) 6 ] is dissolved in the solvent prepared in step 1① to obtain solution A;

[0010] ③ Dissolve polyvinyl pyrrolidone in the solvent prepared in step 1① at room temperature to obtain solution B;

[0011] ④ Add solution B dropwise to solution A at room temperature and stir, then place at 75°C to 80°C for reaction for 18h to 20h, centrifuge and wash in sequence after the reaction to obtain PB, and disperse PB in deionized water to obtain a PB dispersion;

[0012] 2. Preparation of Janus Nano-drug Carriers:

[0013] ① Dissolve polyacrylic acid in water to obtain a polyacrylic acid aqueous solution;

[0014] ② Dissolve 2-methylimidazole in water to obtain a 2-methylimidazole aqueous solution;

[0015] ③ Add the polyacrylic acid aqueous solution to the PB dispersion, and then adjust the pH to 7.8-8.0. After the pH is adjusted, perform ultrasonic dispersion to make it uniform, and then drop isopropanol and CuCl 2 ·2H 2O and stirred to react, centrifuged and washed successively after the reaction to obtain a precipitate B, which was dispersed in deionized water, and a 2-methylimidazole aqueous solution was added and stirred to react, and centrifuged and washed successively after the reaction to obtain a precipitate C, which was dispersed in deionized water, and finally vacuum freeze-dried to obtain a Janus nano drug carrier for enhancing the generation of active oxygen.

[0016] An application of a Janus nano drug carrier for enhancing the generation of active oxygen, which is used for chemodynamic therapy, photothermal therapy and drug loading; the drug is an antibacterial drug or an anticancer drug.

[0017] The beneficial effects of the present invention are:

[0018] The Janus nano drug carrier (PBCM) prepared by the present invention uses a high molecular weight polymer polyacrylic acid with good biocompatibility, degradability and bioadsorption as a template to form a Cu-MOF on one side of the PB, which can significantly improve the PB catalytic H 2 O 2 The presence of copper ions can also consume glutathione, further contributing to the accumulation of hydroxyl free radicals. 2+ and Fe 3+ Through cyanide charge transfer, it can be used for photothermal therapy. Due to the partial coating of Cu-MOF, the antibacterial drug berberine (BBR) can be physically loaded to obtain the Janus nano drug carrier loaded with BBR (BBR@PBCM). Under 808nm laser irradiation, PBCM and BBR work together to effectively achieve antibacterial effect. At the same time, since BBR also has anti-cancer effects, in theory, nano drugs composed of PBCM loaded with BBR can also be used for cancer.

[0019] In summary, the present invention uses PB as a template, utilizes the coordination effect between the carboxyl group of PAA and copper ions, grows a layer of Cu-MOF on the side of PB, and innovatively prepares a Janus nano drug carrier that enhances the production of active oxygen for the delivery of the antibacterial drug berberine (BBR), thereby improving the efficacy of the drug and achieving efficient combined antibacterial treatment. This nano drug carrier can not only release copper ions in a pH-responsive manner to synergistically enhance the Fenton-like reaction of PB to achieve chemical kinetics and photothermal antibacterial treatment, but also achieve the sustained release of the antibacterial drug berberine. This combined antibacterial treatment method can achieve efficient combined antibacterial treatment while improving the efficacy of the drug.

[0020] Instruction Manual

[0021] Figure 1TEM images of PB, PB-PAA and PBCM prepared in Example 1, A is PB, B is PB-PAA, C is PBCM, and D is a magnified image of PBCM;

[0022] Figure 2 Comparison of the Zeta potential of Cu-MOF, PB prepared in Example 1, and PBCM;

[0023] Figure 3 The SEM and TEM images of the PBCM prepared in Example 1, A is SEM, B is TEM;

[0024] Figure 4 UV-visible absorption spectra of Cu-MOF water dispersion, PB prepared in Example 1, and PBCM;

[0025] Figure 5 Fourier transform infrared spectra of Cu-MOF, PB prepared in Example 1 and PBCM;

[0026] Figure 6 XRD patterns of PB and PBCM prepared in Example 1;

[0027] Figure 7 The XPS Cu2p spectrum of the PBCM prepared in Example 1;

[0028] Figure 8 The concentration dependence test of the photothermal heating of the PBCM prepared in Example 1;

[0029] Fig. 9 The power dependence test of the photothermal heating of the PBCM prepared in Example 1;

[0030] Fig.10 This is the heating-natural cooling curve of the PBCM prepared in Example 1;

[0031] Fig.11 The photostability test of the PBCM prepared in Example 1;

[0032] Fig.12 The active oxygen generation of Cu-MOF, PB prepared in Example 1 and PBCM after 30 min of reaction at pH 5.4, A is PB, B is Cu-MOF, and C is PBCM;

[0033] Fig.13 The active oxygen generation of PBCM prepared in Example 1 with different concentrations after 30 minutes of reaction at pH 5.4;

[0034] Fig.14 The active oxygen generation of PBCM prepared in Example 1 at different reaction times at pH 5.4;

[0035] Fig.15 H 2 O 2 Concentration-dependent PBCM Michaelis-Menten constant fitting results;

[0036] Fig.16 GSH consumption of Cu-MOF, PB prepared in Example 1 and PBCM at pH 5.4;

[0037] Fig.17 GSH consumption of PBCM prepared in Example 1 at different concentrations under weakly acidic conditions;

[0038] Fig.18 is the standard curve of BBR using water as solvent;

[0039] Fig.19 This is a diagram showing the antibacterial results of the BBR@PBCM prepared in Example 2, which combines photothermal / BBR / Fenton-like reaction against Escherichia coli;

[0040] Fig. 20 This is a diagram showing the antibacterial results of the BBR@PBCM prepared in Example 2 using photothermal / BBR / Fenton reaction combined with anti-Staphylococcus aureus;

[0041] Fig.21 This is a hemolysis experiment of BBR@PBCM prepared in Example 2;

[0042] Fig. 22 Cytotoxicity experiment of BBR@PBCM prepared in Example 2;

[0043] Fig.23 The wound healing status of mice in different treatment groups during the treatment process;

[0044] Fig.24 These are representative photos of bacterial growth in wound tissues of each group on the fifth day of treatment;

[0045] Fig.25 These are the corresponding real-time thermal imaging photos of mice in different treatment groups under 808nm laser irradiation;

[0046] Fig.26 The temperature change curves of mice in different treatment groups under 808nm laser irradiation;

[0047] Fig. 27 H&E staining pictures of wound tissues of mice in different treatment groups on the 3rd and 8th days of treatment;

[0048] Fig.28 This is a line graph of weight changes of mice in different treatment groups during treatment;

[0049] Fig.29H&E staining pictures of the main organs of mice in the control group and experimental group on the 8th day of treatment;

[0050] Fig.30 The blood biochemical indexes of mice in different treatment groups after 8 days of treatment, A is total bilirubin, B is alanine aminotransferase, C is aspartate aminotransferase, D is alkaline phosphatase (ALP), E is CREA, and F is urea; Control, I is S. aureus + PBS + NIR, II is S. aureus + PBS + H 2 O 2 , III is S. aureus+PBS+NIR+H 2 O 2 , Ⅳ is S. aureus+PB+NIR+H 2 O 2 , V is S.aureus+Cu-MOF+NIR+H 2 O 2 VI is S. aureus+PBCM+NIR+H 2 O 2 VII: S. aureus+BBR@PBCM-100μg / mL+NIR+H 2 O 2 , VIII is S. aureus+BBR@PBCM-200μg / mL+NIR+H 2 O 2 、Ⅸ:S.aureus+BBR. DETAILED DESCRIPTION

[0051] Specific embodiment 1: This embodiment is a method for preparing a Janus nano drug carrier that enhances the generation of active oxygen, which is carried out according to the following steps:

[0052] 1. Preparation of Prussian Blue PB:

[0053] ① Adjust the pH of deionized water to 1-1.5 to obtain a solvent;

[0054] ② At room temperature, K 3 [Fe(CN) 6 ] is dissolved in the solvent prepared in step 1① to obtain solution A;

[0055] ③ Dissolve polyvinyl pyrrolidone in the solvent prepared in step 1① at room temperature to obtain solution B;

[0056] ④ Add solution B dropwise to solution A at room temperature and stir, then place at 75°C to 80°C for reaction for 18h to 20h, centrifuge and wash in sequence after the reaction to obtain PB, and disperse PB in deionized water to obtain a PB dispersion;

[0057] 2. Preparation of Janus Nano-drug Carriers:

[0058] ① Dissolve polyacrylic acid in water to obtain a polyacrylic acid aqueous solution;

[0059] ② Dissolve 2-methylimidazole in water to obtain a 2-methylimidazole aqueous solution;

[0060] ③ Add the polyacrylic acid aqueous solution to the PB dispersion, and then adjust the pH to 7.8-8.0. After the pH is adjusted, perform ultrasonic dispersion to make it uniform, and then drop isopropanol and CuCl 2 ·2H 2 O and stirred to react, centrifuged and washed successively after the reaction to obtain a precipitate B, which was dispersed in deionized water, and a 2-methylimidazole aqueous solution was added and stirred to react, and centrifuged and washed successively after the reaction to obtain a precipitate C, which was dispersed in deionized water, and finally vacuum freeze-dried to obtain a Janus nano drug carrier for enhancing the generation of active oxygen.

[0061] This embodiment provides a Janus nano drug carrier (PBCM) for enhancing the production of reactive oxygen species, including Prussian blue and a metal organic framework Cu-MOF. The carrier provided in this embodiment itself has the function of enhancing Fenton-like reaction and photothermal therapy, and can be used for antibacterial and anticancer. The nano drug carrier provided in this embodiment can effectively load BBR, and since BBR is widely used in anti-inflammatory, antibacterial, anti-diabetic, and anti-tumor, the Janus nano drug carrier for enhancing the production of reactive oxygen species prepared in this embodiment can be used as a nano carrier for antitumor drugs.

[0062] Among them, the metal organic framework Cu-MOF can specifically release drugs (slightly acidic pH = 4-6) as a carrier of antibacterial drugs, and has good responsiveness. The low oxidation state of copper ions provided by Cu-MOF improves its catalytic effect as a CDT-type Fenton reaction catalyst. And because Cu-MOF can effectively load berberine (BBR), the problem of poor water solubility of BBR is solved. Therefore, the Janus nano drug carrier loaded with BBR was finally prepared, which can play the therapeutic effect of CDT and the photothermal therapy effect of PTT while ensuring biosafety. Because it is loaded with BBR with antibacterial effect, it can play the synergistic therapeutic effect of BBR. This Janus nano drug carrier has the ability to effectively load the anticancer drug BBR, so the nano drug carrier can also be used for CDT, PTT, and chemical synergistic therapy of anti-tumor.

[0063] TEM results show that PBCM has a Janus structure. At the same time, the UV-visible absorption spectrum, Fourier infrared spectrum, scanning electron microscope image, X-ray diffraction, and Zeta potential of PBCM all show the partial coating of PB by Cu-MOF and the successful construction of Janus structure. The obtained PBCM can physically load BBR. The UV-visible absorption spectrum of the material obtained after loading BBR can detect the characteristic absorption peak of BBR, proving the successful loading of BBR.

[0064] The beneficial effects of this embodiment are:

[0065] The Janus nano drug carrier (PBCM) prepared in this embodiment uses a high molecular weight polymer polyacrylic acid with good biocompatibility, degradability, and biosorption as a template to form a Cu-MOF on one side of the PB, which can significantly improve the PB catalytic H 2 O 2 The presence of copper ions can also consume glutathione, further contributing to the accumulation of hydroxyl free radicals. 2+ and Fe 3+ Through cyanide charge transfer, it can be used for photothermal therapy. Due to the partial coating of Cu-MOF, the antibacterial drug berberine (BBR) can be physically loaded to obtain the Janus nano drug carrier loaded with BBR (BBR@PBCM). Under 808nm laser irradiation, PBCM and BBR work together to effectively achieve antibacterial effect. At the same time, since BBR also has anti-cancer effects, in theory, nano drugs composed of PBCM loaded with BBR can also be used for cancer.

[0066] In summary, this embodiment uses PB as a template, utilizes the coordination effect between the carboxyl group of PAA and copper ions, grows a layer of Cu-MOF on the side of PB, and innovatively prepares a Janus nano drug carrier that enhances the production of reactive oxygen for the delivery of the antibacterial drug berberine (BBR), thereby improving the efficacy of the drug and achieving efficient combined antibacterial therapy. This nano drug carrier can not only release copper ions in a pH-responsive manner to synergistically enhance the Fenton-like reaction of PB to achieve chemical kinetics and photothermal antibacterial therapy, but also achieve the sustained release of the antibacterial drug berberine. This combined antibacterial treatment method can achieve efficient combined antibacterial therapy while improving the efficacy of the drug.

[0067] Specific implementation method 2: This implementation method is different from the specific implementation method 1 in that: K described in step 1② 3 [Fe(CN) 6] and the volume ratio of the solvent is 13.1mg:(1-1.1)mL; the mass ratio of the polyvinyl pyrrolidone described in step 1 ③ and the volume ratio of the solvent is 1g:(10-12)mL; the polyvinyl pyrrolidone in solution B described in step 1 ④ and the K in solution A 3 [Fe(CN) 6 The mass ratio of ] is (22-25):1; the concentration of PB in the PB dispersion described in step 1④ is 0.5mg / mL-0.55mg / mL. The rest is the same as the specific implementation mode 1.

[0068] Specific implementation method 3: This implementation method is different from specific implementation method 1 or 2 in that the stirring in step 1④ is performed at room temperature and a rotation speed of 1400 rpm to 1500 rpm for 30 to 35 minutes. The rest is the same as specific implementation method 1 or 2.

[0069] Specific embodiment 4: This embodiment is different from the specific embodiments 1 to 3 in that: the concentration of polyacrylic acid in the polyacrylic acid aqueous solution described in step 2 ① is 0.5 mg / mL to 1 mg / mL; the concentration of 2-methylimidazole in the 2-methylimidazole aqueous solution described in step 2 ② is 20 mg / mL to 21.6 mg / mL; the mass ratio of PB in the PB dispersion described in step 2 ③ to polyacrylic acid in the polyacrylic acid aqueous solution is (0.5 to 0.8): 1; the volume ratio of isopropanol described in step 2 ③ to deionized water in the PB dispersion is (6 to 10): 1; the CuCl in step 2 ③ 2 ·2H 2 The molar ratio of O to polyacrylic acid in the polyacrylic acid aqueous solution is (30-35):1; the CuCl 2 ·2H 2 The molar ratio of O to 2-methylimidazole in the 2-methylimidazole aqueous solution is 1:(5-10). Others are the same as those in the first to third embodiments.

[0070] Specific embodiment 5: This embodiment differs from specific embodiments 1 to 4 in that: in step 2③, a 5M ammonia solution is used to adjust the pH to 7.8-8.0; in step 2③, isopropanol and CuCl are added dropwise. 2 ·2H 2 O and stirred for reaction at room temperature and a rotation speed of 500 rpm to 800 rpm for 2 h to 2.5 h; in step 2 ③, 2-methylimidazole aqueous solution was added and stirred for reaction at room temperature and a rotation speed of 1200 rpm to 1500 rpm for 15 min to 25 min. The rest is the same as the specific embodiments 1 to 4.

[0071] Specific embodiment 6: This embodiment is different from specific embodiments 1 to 5 in that: the mass ratio of the precipitate B described in step 2 ③ to the volume ratio of deionized water is 1 mg: (5-6) mL; the mass ratio of the precipitate C described in step 2 ③ to the volume ratio of deionized water is 1 mg: (6-7) mL. Others are the same as specific embodiments 1 to 5.

[0072] Specific embodiment 7: This embodiment is different from specific embodiments 1 to 6 in that: the vacuum freeze drying described in step 2③ is specifically carried out at a temperature of -25°C to -30°C for 1 to 2 days. The rest is the same as specific embodiments 1 to 6.

[0073] Specific implementation method eight: This implementation method is an application of a Janus nano drug carrier that enhances the generation of active oxygen, which is used for chemodynamic therapy, photothermal therapy and drug loading; the drug is an antibacterial drug or an anticancer drug.

[0074] Specific embodiment 9: This embodiment is different from specific embodiment 8 in that the drug is berberine. The rest is the same as specific embodiment 8.

[0075] Specific embodiment 10: This embodiment is different from specific embodiment 8 or 9 in that: the drug loading is specifically carried out according to the following steps: the Janus nano drug carrier that enhances the production of active oxygen is dissolved in deionized water, and then the drug is added, stirred for 20h to 24h at a temperature of 75°C to 80°C, a stirring speed of 800rp to 1000rpm and protected from light, and then centrifuged and washed by centrifugation in sequence to obtain a precipitate, the precipitate is dispersed in deionized water, and finally vacuum freeze-dried to obtain drug-loaded @PBCM; the mass ratio of the Janus nano drug carrier that enhances the production of active oxygen to the drug is 1: (1 to 2). The rest is the same as specific embodiment 8 or 9.

[0076] The following examples are used to verify the beneficial effects of the present invention:

[0077] Embodiment 1:

[0078] A method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen is carried out according to the following steps:

[0079] 1. Preparation of Prussian Blue PB:

[0080] ① Adjust the pH of deionized water to 1.5 with HCl to obtain a solvent;

[0081] ② At room temperature, K 3 [Fe(CN) 6](0.01mol, 131.7mg) was dissolved in 10mL of the solvent prepared in step 1① to obtain solution A;

[0082] ③ Dissolve 3 g of polyvinyl pyrrolidone in 30 mL of the solvent prepared in step 1① to obtain solution B;

[0083] ④ At room temperature, 30 mL of solution B was added dropwise to 10 mL of solution A, and stirred for 30 min at room temperature and a rotation speed of 1500 rpm, and then placed at a temperature of 80°C for reaction for 20 h. After the reaction, deionized water was used for centrifugal washing at a rotation speed of 10000 rpm for 10 min, and the centrifugal washing was repeated 5 times to obtain PB, and PB was dispersed in deionized water to obtain a PB dispersion;

[0084] The concentration of PB in the PB dispersion is 0.5 mg / mL;

[0085] 2. Preparation of Janus Nano-drug Carriers:

[0086] ① Dissolve polyacrylic acid in water to obtain a polyacrylic acid aqueous solution;

[0087] The concentration of polyacrylic acid in the polyacrylic acid aqueous solution is 1 mg / mL;

[0088] ② Dissolve 2-methylimidazole in water to obtain a 2-methylimidazole aqueous solution;

[0089] The concentration of 2-methylimidazole in the 2-methylimidazole aqueous solution is 21.6 mg / mL;

[0090] ③ Add the polyacrylic acid aqueous solution to the PB dispersion, adjust the pH to 8 with a 5M ammonia solution, disperse evenly by ultrasonication, and then drop isopropanol and CuCl 2 ·2H 2 O and stirred for reaction at room temperature and a rotation speed of 800 rpm for 2 hours, after the reaction, centrifuged and washed for 10 minutes with deionized water at a rotation speed of 2000 rpm, and repeated centrifuged washing 3 times to obtain precipitate B, which was dispersed in deionized water, and a 2-methylimidazole aqueous solution was added and stirred for reaction for 15 minutes at room temperature and a rotation speed of 1500 rpm, after the reaction, centrifuged and washed for 10 minutes with deionized water at a rotation speed of 9000 rpm, and repeated centrifuged washing 5 times to obtain precipitate C, which was dispersed in deionized water, and finally vacuum freeze-dried to obtain a Janus nano drug carrier for enhancing the generation of active oxygen, i.e., PBCM;

[0091] The mass ratio of PB in the PB dispersion to polyacrylic acid in the polyacrylic acid aqueous solution is 0.5:1; the volume ratio of isopropanol to deionized water in the PB dispersion is 6:1; the CuCl 2 ·2H 2 O and the molar ratio of polyacrylic acid in the polyacrylic acid aqueous solution is 35:1; the CuCl 2 ·2H 2 The molar ratio of O to 2-methylimidazole in the 2-methylimidazole aqueous solution is 1:10.

[0092] The mass ratio of the precipitate B to the volume of deionized water is 1 mg:5 mL; the mass ratio of the precipitate C to the volume of deionized water is 1 mg:6 mL.

[0093] The vacuum freeze drying described in step 2 is specifically drying at a temperature of -30°C for 1 day.

[0094] Embodiment 2: It is used for loading drugs; the drug is berberine.

[0095] The drug loading is specifically carried out according to the following steps: 5 mg of Janus nano drug carrier that enhances the production of active oxygen is dissolved in 5 mL of deionized water to obtain a PBCM aqueous solution, 5 mg of berberine is dissolved in 5 mL of deionized water to obtain a berberine aqueous solution, the PBCM aqueous solution and the berberine aqueous solution are mixed, and then stirred for 24 hours at a temperature of 80°C, a stirring speed of 800 rpm and protected from light, and then centrifuged for 10 minutes at a speed of 10000 rpm, and then centrifuged and washed with deionized water for 10 minutes at a speed of 10000 rpm, and the centrifugal washing is repeated 3 times to obtain a precipitate, 6.45 mg of the precipitate is dispersed in 2 mL of deionized water, and finally vacuum freeze-dried for 24 hours at a temperature of -30°C to obtain BBR@PBCM.

[0096] (1) The PBCM prepared in Example 1 was structurally characterized and compared with PB-PAA and Cu-MOF:

[0097] The PB-PAA is obtained by adding a polyacrylic acid aqueous solution to a PB dispersion in step 2 (3) of Example 1, adjusting the pH to 8 and uniformly dispersing by ultrasonication, then dropping isopropanol and stirring for reaction at room temperature and a rotation speed of 800 rpm for 2 hours, and after the reaction, centrifuging and washing with deionized water at a rotation speed of 2000 rpm for 10 minutes, and repeating the centrifugal washing 3 times; the mass ratio of PB in the PB dispersion to the polyacrylic acid in the polyacrylic acid aqueous solution is 0.5:1; and the volume ratio of isopropanol to deionized water in the PB dispersion is 6:1.

[0098] The Cu-MOF is specifically prepared according to the following steps: 6 mL of cupric chloride dihydrate aqueous solution (10 mg / mL) is placed on a magnetic stirrer for stirring. During the stirring process, 1 mL of 2-methylimidazole aqueous solution (0.2 g / mL) is dropped into the cupric chloride dihydrate aqueous solution at a speed of 1 mL / min using a peristaltic pump and the reaction is continued for 15 minutes. After the reaction is completed, a centrifuge is used to centrifuge at 8000 rpm for 10 minutes, and the washing is repeated 3-4 times, and the mixture is dried at 50°C for use.

[0099] Regarding the TEM characterization of PBCM, TEM characterization was performed on the PB prepared in step 1④ of Example 1 and the PBCM prepared in step 2③, respectively, to observe the changes in the morphology and size of PB and PBCM before and after. Figure 1 TEM images of PB, PB-PAA and PBCM prepared in Example 1, A is PB, B is PB-PAA, C is PBCM, and D is a magnified image of PBCM; Figure 1 The PB in A is square and has a particle size of about 74nm. Figure 1 B, 1C and Figure 1 D shows that PB-PAA and PBCM present an asymmetric Janus structure, and the particle size of PBCM increases to about 120nm. Figure 1 B, 1C and Figure 1 The granular substance formed in D is Cu-MOF, that is, Cu-MOF is formed on one side of PB.

[0100] Zeta potential characterization was performed on Cu-MOF aqueous dispersion, PB aqueous dispersion and PBCM aqueous dispersion with a concentration of 100 μg / mL to determine whether Cu-MOF is effectively composited with PB; Figure 2 Comparison of the Zeta potentials of Cu-MOF, PB prepared in Example 1, and PBCM; as can be seen from the figure, the Zeta potential of PBCM changes from negative to weakly negative, which also indicates that positively charged Cu-MOF grows on the side of PBCM.

[0101] SEM and TEM characterization of PBCM was performed to observe its three-dimensional morphology; Figure 3 These are the SEM and TEM images of the PBCM prepared in Example 1, where A is SEM and B is TEM. The Janus structure of the PBCM can be more intuitively seen through the SEM and TEM images.

[0102] The UV-visible absorption spectra of Cu-MOF water dispersion, PB water dispersion and PBCM water dispersion with a concentration of 100 μg / mL were characterized, and the test range was 200nm~900nm. Figure 4UV-visible absorption spectra of Cu-MOF water dispersion, PB and PBCM prepared in Example 1; It can be seen from the measurement of UV-visible absorption spectra that the absorbance of PBCM in the near-infrared is lower than that of PB and higher than that of Cu-MOF, which provides support for the existence of Cu-MOF.

[0103] Fourier transform infrared spectroscopy was used to characterize Cu-MOF, PB and PBCM in the range of 4000 cm -1 -400cm -1 , to observe whether the PBCM was successfully prepared. Figure 5 Fourier transform infrared spectra of Cu-MOF, PB and PBCM prepared in Example 1; PBCM at 1411 cm -1 and 1147cm -1 The absorption peaks of -CC- and -CN- stretching vibrations are attributed to Cu-MOF at 2087 cm -1 and 499cm -1 The vibration absorption peak is attributed to the stretching vibration of C≡N and Fe-CN-Fe in PB, which preliminarily verifies the combination of PB and Cu-MOF structure.

[0104] XRD characterization was carried out on PB and PBCM respectively to observe the changes in the crystal state of the materials before and after the reaction. Figure 6 The XRD patterns of PB and PBCM prepared in Example 1; clear diffraction peaks were observed at 2θ=17.3°, 24.7°, 35.1°, 39.4° and 50.6° in PB and PBCM samples, and the diffraction peaks of both samples corresponded to the XRD standard card of PB (PDF#01-0239), indicating that the prepared PB and PB in the Janus structure both had good crystallinity, and the Janus structure did not change the crystal structure of PB. However, the intensity of the diffraction peak of PBCM decreased significantly, which may be caused by the decrease of PB content in the Janus structure at the same mass.

[0105] XPS characterization was performed on PBCM to determine the valence state of ions in the material. Figure 7 The XPS Cu2p spectrum of the PBCM prepared in Example 1; Figure 7 Four different Cu peaks are shown, which are assigned to Cu 2p3 / 2 and Cu 2p1 / 2 and their satellite peaks. The XPS fine spectrum of Cu2p in PBCM has two obvious satellite peaks, which indicates that the copper ions in Cu-MOF are mainly in the form of Cu 2+ This provides theoretical support for the better catalytic ability of Fenton-like reaction.

[0106] The above structural characterization of PBCM proves the successful preparation of Janus structure.

[0107] (2) The photothermal performance of the PBCM prepared in Example 1 under 808 nm laser excitation was tested, including concentration dependence test, power dependence test, photostability test, and photothermal conversion efficiency test of the PBCM photothermal performance.

[0108] Concentration dependence test of photothermal performance: PBCM prepared in Example 1 was prepared into 3 mL of 25 μg / mL, 50 μg / mL, 100 μg / mL, 200 μg / mL and 400 μg / mL aqueous dispersions, and each dispersion was placed under 808 nm laser (1 W / cm 2 ) for 10 min, record the temperature with an infrared thermal imager, and observe the temperature rise of the material (count once every 30 s). Figure 8 This is the concentration dependence test of the photothermal heating of the PBCM prepared in Example 1; at 1 W / cm 2 After 808nm laser irradiation for 10 minutes, the temperature increased from 25μg / mL to 400μg / mL to 39.0, 42.0, 45.0, 47.2, and 50.6℃. It can be seen that under the same laser irradiation power, the heating effect of PBCM is proportional to the material concentration. The higher the concentration, the better the heating effect of the material.

[0109] Power dependence test of photothermal performance: The PBCM prepared in Example 1 was prepared into five groups of 3 mL of 100 μg / mL aqueous dispersions, and each group of dispersions was placed under different powers (0.5 W / cm 2 , 1.0W / cm 2 , 1.5W / cm 2 , 2.0W / cm 2 ) for 10 min, record the temperature with an infrared thermal imager, and observe the temperature rise of the material (one time every 30 s). Fig. 9 This is the power dependence test of the photothermal heating of the PBCM prepared in Example 1. It can be seen that the heating effect of the material is power-dependent. After 808nm laser irradiation for 10min, the heating effect of the material increases from 0.5W / cm 2 Up to 2W / cm 2 The temperature increases to 39.1, 45.0, 54.7, and 61.3°C in sequence, that is, at the same concentration, the greater the laser irradiation power, the better the heating effect of the material.

[0110] Test of PBCM photothermal conversion efficiency (η): PBCM prepared in Example 1 was prepared into 3 mL of 100 μg / mL aqueous dispersion and placed under 808 nm laser (1 W / cm 2) until the temperature reaches equilibrium, turn off the laser to allow the dispersion to cool to room temperature, and record the temperature with an infrared thermal imager (count once every 30 seconds). Fig.10 This is the heating-natural cooling curve of the PBCM prepared in Example 1; the light-to-heat conversion efficiency of the material is calculated to be 30.44%.

[0111] Photostability test of PBCM: In order to verify the stability of the light response ability of PBCM after multiple laser irradiation and natural cooling, the PBCM prepared in Example 1 was prepared into 3 mL of 100 μg / mL aqueous dispersion and placed under 808 nm laser (1 W / cm 2 ) for 10 min, then turn off the laser and wait for the dispersion to cool naturally to room temperature, then repeat the process four times, and record the temperature with an infrared thermal imager (one time every 30 s). Fig.11 This is a photostability test of the PBCM prepared in Example 1; after five repeated heating and cooling, the PBCM still has a stable photothermal heating capability, and each heating can reach above 50°C, which shows that the PBCM has good photostability.

[0112] (3) The catalytic ability of Cu-MOF, PB prepared in Example 1, and PBCM in the Fenton-like reaction was compared. TMB (3,3',5,5'-tetramethylbenzidine) was used as a substrate to verify the catalytic performance of different materials in the presence of glutathione GSH. 2 O 2 The strength of the catalytic ability to produce a Fenton-like reaction.

[0113] Phosphate buffer solution (PBS, pH = 7.4) was used to prepare PB, Cu-MOF and PBCM solutions with a concentration of 1 mg / mL, and PBS (pH = 5.4) was used to prepare GSH solutions with a concentration of 10 mM and H 2 O 2 Solution: Use DMSO to prepare a TMB solution at a concentration of 1 mg / mL.

[0114] TMB was used to detect the effect of different materials on the catalytic ability of Fenton-like reaction in the presence of GSH: a certain amount of each group of solutions prepared above was added to a 3 mL system to make the system pH 5.4, the TMB concentration in the system was 50 μg / mL, the concentration of each group of materials (Cu-MOF, PB or PBCM) was 50 μg / mL, and the H 2 O 2The concentration was 1mM, and the GSH concentration was (0.2, 1, 2mM) according to the group. After all the solutions were added, they were fully mixed and then placed in a 37°C oven in the dark for 30 minutes. After the reaction of each group was completed, in order to prevent the interference of ultraviolet absorption of nanomaterials, the mixed solution was centrifuged (10000rpm for 5 minutes) and then the absorbance value of each group at 652nm of the supernatant was detected by UV-visible spectrophotometer to verify the generation of reactive oxygen species under the influence of different concentrations of GSH in PB, Cu-MOF and PBCM; the addition of GSH is intended to intuitively reflect the deficiencies and limitations of PB and Cu-MOF in chemokinetic therapy. Fig.12 Figure 2 is the active oxygen generation of Cu-MOF, PB prepared in Example 1 and PBCM after 30 min of reaction at pH 5.4, where A is PB, B is Cu-MOF, and C is PBCM; Fig.12 As shown in A&B, with the increase of GSH concentration, the ROS production rate of PB and Cu-MOF groups decreased significantly. This is because most of the ROS produced were consumed by GSH due to its reducibility. PBCM also showed a downward trend ( Fig.12 C), but its decreasing trend is much lower than that of PB and Cu-MOF groups, which may be attributed to the Cu + Mediated by Fe 3+ To Fe 2+ The conversion and its own function of generating active oxygen synergistically enhance the yield of active oxygen.

[0115] The effect of different material concentrations on the catalytic ability of the material in the Fenton-like reaction was detected by TMB: a certain amount of each group of solutions prepared above was added to a 3 mL system to make the system pH 5.4. The TMB concentration in the system was 50 μg / mL, different concentrations of PBCM (5 μg / mL, 10 μg / mL, 15 μg / mL or 20 μg / mL), H 2 O 2 The concentration is 1mM and the concentration of GSH is 1mM. After all the solutions are added, they are fully mixed and then placed in a 37°C oven in the dark for 2 hours. The mixed solution is centrifuged (10000rpm for 5 minutes) and then the absorbance value of each group of the supernatant at 652nm is detected using a UV-visible spectrophotometer. Fig.13 Figure 3 shows the generation of active oxygen when PBCM prepared in Example 1 with different concentrations reacts for 30 minutes at a pH of 5.4. As can be seen from the figure, as the concentration of PBCM increases, the degree of oxidation of TMB by PBCM becomes stronger, that is, as the concentration of PBCM increases, more active oxygen is generated by PBCM.

[0116] TMB detection of the effect of different reaction times on the catalytic ability of the material in the Fenton-like reaction: In a 3 mL system, a certain amount of each group of solutions prepared above was added to make the system pH 5.4, the TMB concentration in the system was 50 μg / mL, the PBCM concentration was 50 μg / mL, and the H 2 O 2 The concentration was 1mM and the GSH concentration was 1mM. After all the solutions were added, they were fully mixed and then placed in a 37°C oven in the dark for incubation for 5, 10, 15, 30, 45, 60, 75 and 90 min. The mixed solution was centrifuged (10000 rpm for 5 min) and then the absorbance of each group of supernatants at 652 nm was detected using a UV-visible spectrophotometer. Fig.14 The figure shows the active oxygen production of the PBCM prepared in Example 1 at different reaction times at a pH of 5.4. As can be seen from the figure, the active oxygen production in the system increases with time.

[0117] PBCM in H 2 O 2 Michaelis constant under concentration change: In a 3mL system, a certain amount of each group of solutions prepared above was added to make the system pH 5.4, the TMB concentration in the system was 50μg / mL, the PBCM concentration was 10μg / mL, and the H 2 O 2 Concentrations (0.1, 0.2, 0.3, 0.4, 0.5, 1 mM), GSH concentration 1 mM. After all solutions were added, they were fully mixed and then placed in a 37°C oven in the dark for 30 min. The absorbance was measured at 652 nm using an ELISA reader. According to the Beer-Lambert law, the initial rate of absorbance change was converted into the initial rate of oxidized TMB generation (V 0 ), with the addition of H 2 O 2 The concentration corresponds to v(H 2 O 2 ), and c(H 2 O 2 ) were used to perform Michaelis Menten fitting and double reciprocal linear fitting. Fig.15 H 2 O 2 The concentration-dependent PBCM Michaelis-Menten constant fitting results; the left figure is a typical Michaelis-Menten curve, and the right figure is a double reciprocal linear graph Lineweaver-Burk graph made based on the data on the left figure; the Michaelis-Menten constant (Km) and the maximum initial velocity (Vmax) are obtained from the fitting, and km(H 2 O 2 )=0.07mM,Vmax(H2 O 2 )=8.11×10 -8 M.S. -1 , showing that PBCM can bind well to the substrate and exert Fenton-like reaction catalytic ability.

[0118] The above-mentioned test on the catalytic ability of PBCM for Fenton-like reactions shows that PBCM has excellent catalytic ability for Fenton-like reactions in an acidic environment.

[0119] (4) The consumption capacity of PBCM prepared in Example 1 on glutathione (GSH) in a weakly acidic environment was investigated. The principle is that DTNB (5,5'-dithio-bis-(2-nitrobenzoic acid)) can react with glutathione (GSH) to produce 2-nitro-5-mercaptobenzoic acid and glutathione disulfide (GSSG). Since 2-nitro-5-mercaptobenzoic acid is a yellow product, the content of glutathione in the sample can be determined by measuring its maximum absorption at 412 nm. The product after GSH is oxidized by the material will not produce this characteristic absorption peak, so the consumption capacity of the material on GSH can be judged.

[0120] 3 mL of the system was prepared, the pH of the system was 5.4, the concentration of each group of materials (Cu-MOF, PB or PBCM) in the system was 50 μg / mL, and the GSH concentration was 0.2 mM. Then, it was incubated at 37°C in the dark for 30 min, centrifuged at 10000 rpm for 5 min, 10 μL of DTNB (0.2 mM) was added, and the mixture was shaken on a vortexer. It was then incubated at 37°C in the dark for 10 min, and the UV-visible absorption spectrum of the material was tested. Fig.16 The figure shows the GSH consumption of Cu-MOF, PB prepared in Example 1 and PBCM at pH 5.4. As can be seen from the figure, the PB group consumed very little GSH, while the Cu-MOF and PBCM groups had consumed all the GSH in the system.

[0121] 3 mL of the system was prepared with a pH of 5.4. The concentrations of PBCM in the system were (12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL) and the concentration of GSH was 1 mM. The system was then incubated at 37°C in the dark for 30 min. After centrifugation at 10,000 rpm for 5 min, 10 μL of DTNB (0.2 mM) was added, the system was shaken on a vortex machine, and the system was incubated at 37°C in the dark for 10 min. Finally, the UV-visible absorption spectrum of the material was tested. Fig.17The figure shows the GSH consumption of PBCM prepared in Example 1 at different concentrations under weakly acidic conditions. As can be seen from the figure, as the concentration of PBCM increases, GSH is correspondingly consumed more, indicating that the copper ions that are rapidly dissociated and released by PBCM in a weakly acidic environment can react with GSH efficiently, and while playing the role of CDT in the antibacterial application of PBCM, the consumption of active oxygen by GSH can be effectively reduced to obtain better antibacterial effects.

[0122] (5) The loading rate, encapsulation rate and sustained release of BBR were measured for the BBR@PBCM prepared in Example 2.

[0123] First, a 3 mL aqueous solution of BBR with a concentration gradient was prepared, and the UV-visible absorption spectrum was measured, and a standard curve of BBR with water as the solvent was drawn. The BBR@PBCM prepared in Example 2 was centrifuged and washed three times with deionized water to obtain a precipitate, and the supernatant was collected for the measurement of the UV-visible absorption spectrum, and compared with the standard curve of BBR with water as the solvent to calculate the BBR loading rate and encapsulation rate of the material. Fig.18 is the standard curve of BBR with water as solvent; through calculation, it can be concluded that the drug loading of BBR@PBCM prepared in Example 2 is 29.59% and the encapsulation efficiency is 42.04%. This can reflect the effective loading of PBCM on BBR, which is helpful for the subsequent release of BBR for antibacterial effect.

[0124] In a 37°C system, BBR@PBCM was dispersed in PBS with different pH values ​​(pH=7.4 and pH=5.4), and BBR@PBCM was placed in a dialysis bag for dialysis simulation drug release. At a specific time point, 1 mL of release medium was taken out and an equal volume of fresh release medium was added. The absorbance of the supernatant samples collected at each time point was measured at 263 nm using a UV-visible spectrophotometer. It was found that berberine was basically not released in the first 5 hours under the condition of pH=7.4, and the cumulative berberine release of BBR@PBCM at pH=7.4 reached 11.07±0.38% at 24 hours. Since MOF is highly acid-sensitive, the MOF part of BBR@PBCM will degrade under acidic conditions. Due to the destruction of the structure of MOF, the berberine inside it will be exposed and released. Finally, the cumulative release of berberine in BBR@PBCM at pH=5.4 at 24 hours was 55.17±1.29%.

[0125] (6) Using the BBR@PBCM prepared in Example 2, the experimental conditions (with or without exogenous H 2 O 2The photothermal / BBR / Fenton-like reaction catalytic combined antibacterial test was carried out with and without near-infrared laser irradiation. The two representative bacteria selected were Gram-positive Staphylococcus aureus (S. aureus) and Gram-negative Escherichia coli (E. coli).

[0126] BBR@PBCM anti-E. coli test: well-grown E. coli was placed in 20 mL of sterile nutrient broth medium, and activated at an appropriate speed in a shaker at 37°C for 16 h to obtain an E. coli suspension. The E. coli suspension was transferred to a sterile centrifuge tube, centrifuged at 5000 rpm for 5 minutes, and then washed several times with a sterile PBS solution with a pH of 5.4. Finally, the E. coli suspension was diluted to 10 with PBS. 8 CFU (OD 600 =0.5) for standby. Set BBR@PBCM(NIR), BBR@PBCM(H 2 O 2 ) and BBR@PBCM(NIR+H 2 O 2 ) three groups. 300 μL of bacterial solution was added to the 48-well plate, and then 0, 30, 60, 120, 180, and 240 μL of 500 μg / mL BBR@PBCM dispersion were added to the wells, respectively, so that the final concentration of BBR@PBCM in each group was 0, 25, 50, 100, 150, and 200 μg / mL, respectively. BBR@PBCM (H 2 O 2 ) and BBR@PBCM(NIR+H 2 O 2 ) group added 60 μL of H 2 O 2 (10 mM), BBR@PBCM (H 2 O 2 ) and BBR@PBCM(NIR+H 2 O 2 ) Group H 2 O 2 The final concentration was 1 mM, and the rest was filled with sterile PBS. The above-mentioned well plate was placed on a well plate shaker and fully mixed. The well plate was fully incubated at 37°C for 30 minutes, and then an 808nm laser was used at 1.5W·cm -2 The power of BBR@PBCM(NIR) and BBR@PBCM(NIR+H 2 O 2 ) group was irradiated for 10 min, and the non-photothermal group received no additional treatment.

[0127] BBR@PBCM anti-Staphylococcus aureus test: well-grown Staphylococcus aureus was placed in 20 mL of sterile nutrient broth medium, and activated at an appropriate speed in a shaker at 37°C for 16 h to obtain a Staphylococcus aureus suspension. The Staphylococcus aureus suspension was transferred to a sterile centrifuge tube, centrifuged at 5000 rpm for 5 minutes, and then washed several times with a sterile PBS solution with a pH of 5.4. Finally, the Staphylococcus aureus suspension was diluted to 10 with PBS. 8 CFU (OD 600 =0.5) for standby. Set BBR@PBCM(NIR), BBR@PBCM(H 2 O 2 ) and BBR@PBCM(NIR+H 2 O 2 ) three groups. 300 μL of bacterial solution was added to the 48-well plate, and then 0, 30, 60, 120, 180, and 240 μL of 500 μg / mL BBR@PBCM dispersion were added to the wells, respectively, so that the final concentration of BBR@PBCM in each group was 0, 25, 50, 100, 150, and 200 μg / mL, respectively. BBR@PBCM (H 2 O 2 ) and BBR@PBCM(NIR+H 2 O 2 ) group added 60 μL of H 2 O 2 (10 mM), BBR@PBCM (H 2 O 2 ) and BBR@PBCM(NIR+H 2 O 2 ) Group H 2 O 2 The final concentration was 1 mM, and the rest was filled with sterile PBS. The above-mentioned well plate was placed on a well plate shaker and fully mixed, and the well plate was fully incubated at 37°C for 30 minutes, and then an 808nm laser was used at 1.5W·cm -2 The power of BBR@PBCM(NIR) and BBR@PBCM(NIR+H 2 O 2 ) group was irradiated for 10 min, and the non-photothermal group received no additional treatment.

[0128] Fig.19 This is a diagram showing the antibacterial results of the BBR@PBCM photothermal / BBR / Fenton-like reaction combined with anti-Escherichia coli prepared in Example 2; Fig. 20 This is the antibacterial result diagram of the BBR@PBCM prepared in Example 2, which combines photothermal / BBR / Fenton reaction against Staphylococcus aureus; Fig.19As shown in the experimental results, it is found that BBR@PBCM (H 2 O 2 -1mM) treatment group can achieve a relatively good antibacterial effect in a short time (30min). -2 ) treatment group also showed similar antibacterial effects. The above two treatment groups can have relatively good antibacterial effects, which are attributed to the synergistically enhanced CDT effect and the relatively good photothermal effect of BBR@PBCM. By comparison, it was found that BBR@PBCM (NIR-1.5W·cm -2 , H 2 O 2 -1mM) group, the number of bacteria decreased rapidly with the gradual increase of BBR@PBCM concentration. This is attributed to the synergistic effect of the triple treatment of BBR@PBCM. As the temperature increases, the permeability of the bacterial membrane changes, making it easier for BBR@PBCM to enter the bacteria. After entering the bacteria, the rapid consumption of GSH inside the bacteria and the synergistic enhancement of reactive oxygen species will destroy the redox balance inside the bacteria. With the continuous release of berberine, E. coli is finally completely inhibited. The inhibition experiment of S. aureus showed slightly different results from E. coli. BBR@PBCM (H 2 O 2 The antibacterial effect of the BBR@PBCM treatment group was not obvious compared with the PBS group until the BBR@PBCM reached a higher concentration ( Fig. 20 ). This may be attributed to the different structures of the two bacteria. The outer membrane of E. coli is composed of multiple layers of loose porous peptidoglycan, while the dense lipopolysaccharide (LPS) and lipoprotein structure outside the cell wall of S. aureus act as a barrier. This makes S. aureus less sensitive to reactive oxygen species within a certain range. Studies have shown that berberine is more selective for S. aureus, so BBR@PBCM (NIR-1.5W·cm -2 The antibacterial effect of the BBR@PBCM (NIR-1.5W·cm -2 , H 2 O 2 -1 mM) treatment group showed slightly better results than E. coli, which may be largely due to the stronger selectivity of berberine for S. aureus.

[0129] The above-mentioned photothermal / BBR / Fenton-like reaction combined antibacterial test on BBR@PBCM shows that BBR@PBCM has the photothermal / BBR / Fenton-like reaction catalytic combined antibacterial ability.

[0130] (7) The BBR@PBCM prepared in Example 2 was subjected to a hemolysis experiment. 0.75 mL of fresh mouse blood was placed in a centrifuge tube containing EDTA-2K, mixed repeatedly to prevent blood coagulation, and then centrifuged at 2000 rpm for 2 min to collect red blood cells. After washing the blood cells with cold PBS until the supernatant was colorless, 5 mL of PBS was added to disperse the red blood cells into a stock solution. Subsequently, 0.5 mL of red blood cell stock solution was fully mixed with 0.5 mL of BBR@PBCM of different concentrations in a centrifuge tube to make the final concentration of BBR@PBCM (0, 25, 50, 100, 150, 200, 400 μg / mL), and incubated at 37 ° C for 2 h. At the same time, deionized water was used as a positive control, and PBS buffer was used as a negative control. After the incubation was completed, the red blood cell stock solution was centrifuged at 2000 rpm for 2 min and photographed and recorded. Finally, 100 μL of the supernatant was aspirated into a 96-well plate, and the absorbance was measured at 540 nm using an ELISA reader, with three replicate wells set for each group.

[0131] Dental pulp stem cells (DPSCs) were used to evaluate the acute toxicity of BBR@PBCM. DPSCs were cultured at 8×10 3 The cells were seeded into 96-well plates at a density of 100 cells / mL and cultured in Dulbecco's modified Eagle's medium (DMEM) (containing 10% fetal bovine serum and 1% penicillin-streptomycin) and then incubated in a humidified incubator at 37°C (5% CO). 2 ) for 12 h to allow cell attachment. The cell culture medium was replaced with fresh cell culture medium containing BBR@PBCM (25 μg / mL to 400 μg / mL) and incubated for another 24 h; finally, MTT was used to detect cell viability.

[0132] Fig.21 This is a hemolysis experiment of BBR@PBCM prepared in Example 2; Fig. 22 Cytotoxicity experiment of BBR@PBCM prepared in Example 2; acute toxicity evaluation of BBR@PBCM, such as Fig.21 It can be seen that the material still has a very low hemolysis rate (4.21%) at a maximum concentration of 400 μg / mL, indicating the biosafety of the material. Fig. 22 It can be seen that the material has almost no toxicity to normal human dental pulp cells at higher concentrations, and the cell survival rate using 400 μg / mL BBR@PBCM can still be controlled above 85%, indicating the biosafety of the material.

[0133] The above-mentioned test on the acute toxicity of BBR@PBCM shows that BBR@PBCM has low acute toxicity and good biosafety.

[0134] (8) The BBR@PBCM prepared in Example 2 was used to conduct a mouse experiment to explore the effect of CDT, PTT and berberine combined antibacterial treatment on animals. Staphylococcus aureus (S. aureus) was used to construct a mouse model of bacterial infection.

[0135] Construction of bacterial infection animal model: First, the mice were prepared for the experiment, and the appropriate location on the back of the mice was shaved and hair removed. Then the mice were anesthetized, and a dose of 150 μL / 10g of Avertin was injected into the mouse's peritoneum. After disinfection with 75% ethanol, a circular wound with a diameter of about 10 mm was cut on the pre-selected part of the mouse's body. 100 μL of the prepared Staphylococcus aureus solution (10 8 CFU) were inoculated into the wound and incubated for 24 h to construct a mouse model of wound infection.

[0136] In vivo antibacterial test of BBR@PBCM: After the wound bacterial infection model was successfully established, the mice were randomly divided into PBS, PBS+NIR, PBS+H 2 O 2 , PBS+NIR+H 2 O 2 、BBR@PBCM-100μg / mL+NIR+H 2 O 2 、BBR@PBCM-200μg / mL+NIR+H 2 O 2 PB+NIR+H 2 O 2 (PB concentration is 100 μg / mL), Cu-MOF+NIR+H 2 O 2 (Cu-MOF concentration is 100 μg / mL), PBCM+NIR+H 2 O 2 (PBCM concentration was 100 μg / mL), BBR (200 μg / mL), 10 groups. Each group had no less than five mice.

[0137] Evaluation of wound infection healing: First, mice were anesthetized with Avertin. After the mice were fixed, 100 μL of the treatment solution was dripped onto the infected part of the mice using a pipette according to the above grouping. Mice in the treatment group with laser irradiation were treated with an 808 nm laser emitter at 1.5 W·cm -2 The laser power density was irradiated for 5 min, and the temperature change was monitored and photographed using an infrared thermal imager. No additional treatment was given to the non-irradiated group. 2 O 2The final concentration is 1mM, and the material needs to be used simultaneously with H during the treatment process. 2 O 2 The experimental group of materials and H 2 O 2 It needs to be mixed before use, and then dripped onto the infected wound of mice for treatment after being fully mixed. The healing of the wounds of mice was measured, photographed and recorded every other day, and the weight changes of mice during the treatment were monitored. Fig.23 The wound healing conditions of mice in different treatment groups during treatment; BBR@PBCM was tested for in vivo antibacterial effects. Fig.23 As shown in the figure, the wound images on day 0 showed that the wounds of the mice were red and swollen without scabs and had white secretions, which indicated the effective infection of the mouse wounds by Staphylococcus aureus and the successful establishment of the mouse wound infection model. During the entire 10-day treatment process, the wounds of the mice in both the experimental and control groups showed a gradual healing state, while the wounds of the PBS group still had scabs on the 10th day of treatment. During the treatment process, the macroscopic images of the wounds in different treatment groups at different time points showed that the introduction of trace amounts of H 2 O 2 The BBR@PBCM (200 μg / mL) group irradiated with near-infrared radiation accelerated the closure of S. aureus infected wounds, while the wound healing in the other groups was significantly inhibited.

[0138] Wound flora smearing: On the fifth day of mouse treatment, use a sterile cotton swab to pick up bacteria from the mouse wound, place the cotton swab in 0.5 mL of sterile saline, soak and mix thoroughly, then take 60 μL of the mixture and smear it on the sterile nutrient agar medium prepared in advance, place the culture medium upside down in an incubator and culture it. After 18 hours, take pictures of the flora on the plate and count them. Fig.24 The representative photos of the bacterial flora growth in the wound tissue of each group on the fifth day of treatment; in order to prove that the BBR@PBCM activated by the infection microenvironment has a highly efficient synergistic effect in vivo, the bacteria washed out from the wound tissue were cultured in agar culture dishes. Fig.24 It can be seen that BBR@PBCM-200μg / mL+NIR+H 2 O 2 The colony count of the group was much lower than that of the other groups, showing good in vivo antibacterial activity.

[0139] Fig.25 These are the corresponding real-time thermal imaging photos of mice in different treatment groups under 808nm laser irradiation; Fig.26The temperature change curves of mice in different treatment groups under 808nm laser irradiation are shown below. The increase in PTT-induced temperature can cause vasodilation in the inflammatory area, further alleviating hypoxia in the infected microenvironment, thereby improving oxygen perfusion and promoting a variety of oxygen-dependent treatments. Therefore, an infrared thermal imager was used to record the photothermal therapeutic effect of BBR@PBCM in the treatment of wound bacterial infection ( Fig.25 ). After 5 min of near-infrared laser irradiation, BBR@PBCM-200 μg / mL+NIR+H 2 O 2 The surface temperature of the infected wound in the group increased to 50℃ ( Fig.26 ), which is sufficient to effectively eliminate S. aureus. It is worth noting that such a temperature can promote CDT and activate BBR@PBCM, so that BBR@PBCM kills bacteria through the release of heat, reactive oxygen species and berberine, while reducing adverse effects on surrounding normal tissues.

[0140] H&E staining of mouse wound tissue sections: On the third day of antibacterial treatment of mice and after the treatment was completed, one mouse was randomly selected from each group and killed. The wound tissue of the mouse was obtained and fixed with 4% paraformaldehyde, and then embedded with prepared paraffin after dehydration, and then sliced ​​after solidification. The prepared slices were stained with hematoxylin-eosin staining (H&E staining), and the morphological structure of the mouse wound was observed using an optical microscope after successful staining. Fig. 27 H&E staining pictures of wound tissues of mice in different treatment groups on the 3rd and 8th days of treatment; on the third day of treatment, obvious epidermal rupture and inflammation were observed in the wound tissues of each group. 2 O 2 and BBR@PBCM-200μg / mL+NIR+H 2 O 2 Re-epithelialization and reduced inflammation of the wound were observed in the treated groups on day 8, where BBR@PBCM-200 μg / mL+NIR+H 2 O 2 What's more, the growth of hair follicles at the wound site recovers better with the higher concentration of the material, which shows that BBR@PBCM can effectively fight bacteria at the wound site and promote wound recovery.

[0141] The above analysis of the in vivo antibacterial test of BBR@PBCM shows that BBR@PBCM has a good CDT / PTT / BBR combined antibacterial treatment effect, which can effectively kill bacteria in wound infections and promote wound healing.

[0142] (9) The biocompatibility of the BBR@PBCM prepared in Example 2 was tested. In addition to the above-mentioned acute toxicity test of the materials, the biocompatibility of BBR@PBCM can also be determined by the weight change of mice in the mouse experiment, H&E staining of mouse organ sections, and detection of mouse blood biochemical indicators. The negative impact of BBR@PBCM on the health of mice can be determined by the effect of BBR@PBCM on the weight gain of healthy mice of appropriate age.

[0143] Fig.28 The following is a line graph showing the weight changes of mice in different treatment groups during treatment. The following was obtained by recording the weight changes of 10 groups of mice in experiment (8) from the 0th day to the 10th day of treatment. Fig.28 The results show that starting from the 0th day of treatment, the weight of mice in the control group without BBR@PBCM and the experimental group with BBR@PBCM showed a steady growth trend, and on the 8th day of treatment, the weight of mice in each group was not much different, which shows that the growth of mice of appropriate age used in this experiment was not affected by BBR@PBCM, H 2 O 2 Compared with the influence of NIR, on the 8th day, the average weight of mice in each group was almost around 30g, which also shows that BBR@PBCM has good biocompatibility and the side effects of using BBR@PBCM for antibacterial treatment on mice are not obvious.

[0144] H&E staining of mouse organ sections: After 8 days of treatment in experiment (8), mice in all groups were killed and PBS+H 2 O 2 +NIR group and BBR@PBCM (200 μg / mL) +H 2 O 2 The hearts, livers, spleens, lungs, and kidneys of the mice in the +NIR group were fixed with 4% paraformaldehyde, embedded with prepared paraffin after dehydration, and sliced ​​after solidification. The slices were stained with hematoxylin-eosin staining (H&E staining), and the morphological structures of the various organs of the mice were observed using an optical microscope after successful staining. Fig.29 These are H&E staining images of the main organs of mice in the control group and the experimental group on the 8th day of treatment; the slice samples of each organ were prepared by dehydrating, embedding, slicing, and staining the mouse organ tissues, and then observed and photographed using an optical microscope. Fig.29 The results of the two groups of H&E staining images showed that after 8 days of treatment, the morphology of the five major organs in the control group and the experimental group all showed normal state, and no obvious morphological changes and inflammation were found. This not only shows that the H&E used in the treatment process 2 O 2NIR does not cause harm to the mice's bodies, and proves that BBR@PBCM has good biosafety.

[0145] Detection of mouse blood biochemical indices: After 8 days of treatment in experiment (8), one mouse was randomly selected from each group and 2 mL of blood was collected through the eyeball and placed in an anticoagulant centrifuge tube. The blood was mixed repeatedly to prevent blood coagulation, and then centrifuged at 2000 rpm for 5 min to collect the serum in a centrifuge tube and stored at -20°C. A blood biochemical kit was then used to detect several mouse blood indices (ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; UREA: urea; T-BIL: total bilirubin; CREA: creatinine). Fig.30 The blood biochemical indexes of mice in different treatment groups after 8 days of treatment, A is total bilirubin, B is alanine aminotransferase, C is aspartate aminotransferase, D is alkaline phosphatase (ALP), E is CREA, and F is urea; Control, I is S. aureus + PBS + NIR, II is S. aureus + PBS + H 2 O 2 , III is S. aureus+PBS+NIR+H 2 O 2 , Ⅳ is S. aureus+PB+NIR+H 2 O 2 , V is S.aureus+Cu-MOF+NIR+H 2 O 2 VI is S. aureus+PBCM+NIR+H 2 O 2 VII: S. aureus+BBR@PBCM-100μg / mL+NIR+H 2 O 2 , VIII is S. aureus+BBR@PBCM-200μg / mL+NIR+H 2 O 2 , IX: S. aureus + BBR; By comparing the control group with the experimental group, the results showed that although the data of each group were different from the PBS group, they were still within the normal range. These results showed that there was no obvious toxic effect on the heart, liver or kidney in any treatment group.

[0146] The above biocompatibility tests show that BBR@PBCM has good biocompatibility while exerting efficient CDT / PTT / BBR combined antibacterial treatment effects without causing obvious toxic side effects to organisms.

Claims

1. A method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen, characterized in that It is carried out in the following steps:

1. Preparation of Prussian Blue PB: ① Adjust the pH of deionized water to 1-1.5 to obtain a solvent; ② Dissolve K3[Fe(CN)6] in the solvent prepared in step 1① at room temperature to obtain solution A; ③ Dissolve polyvinyl pyrrolidone in the solvent prepared in step 1① at room temperature to obtain solution B; ④ Add solution B dropwise to solution A at room temperature and stir, then place at 75°C to 80°C for reaction for 18h to 20h, centrifuge and wash in sequence after the reaction to obtain PB, and disperse PB in deionized water to obtain a PB dispersion; 2. Preparation of Janus Nano-drug Carriers: ① Dissolve polyacrylic acid in water to obtain a polyacrylic acid aqueous solution; ② Dissolve 2-methylimidazole in water to obtain a 2-methylimidazole aqueous solution; ③ Add the polyacrylic acid aqueous solution to the PB dispersion, and then adjust the pH to 7.8-8.

0. After the pH is adjusted, ultrasonic dispersion is performed uniformly, and then isopropanol and CuCl2·2H2O are added dropwise and stirred for reaction. After the reaction, centrifugal washing is performed in sequence to obtain precipitate B. The precipitate B is dispersed in deionized water, and a 2-methylimidazole aqueous solution is added and stirred for reaction. After the reaction, centrifugal washing is performed in sequence to obtain precipitate C. The precipitate C is dispersed in deionized water, and finally vacuum freeze-dried to obtain a Janus nano-drug carrier for enhancing the generation of active oxygen.

2. The method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 1, characterized in that The mass ratio of K3[Fe(CN)6] described in step 1② to the volume ratio of the solvent is 13.1 mg:(1~1.1) mL; the mass ratio of polyvinyl pyrrolidone described in step 1③ to the volume ratio of the solvent is 1 g:(10~12) mL; the mass ratio of polyvinyl pyrrolidone in solution B described in step 1④ to K3[Fe(CN)6] in solution A is (22~25):1; the concentration of PB in the PB dispersion described in step 1④ is 0.5 mg / mL~0.55 mg / mL.

3. The method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 1, characterized in that The stirring described in step 1④ is specifically stirring for 30min to 35min at room temperature and a rotation speed of 1400rpm to 1500rpm.

4. The method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 1, characterized in that The concentration of polyacrylic acid in the polyacrylic acid aqueous solution described in step 2① is 0.5mg / mL~1mg / mL; the concentration of 2-methylimidazole in the 2-methylimidazole aqueous solution described in step 2② is 20mg / mL~21.6mg / mL; the mass ratio of PB in the PB dispersion described in step 2③ to polyacrylic acid in the polyacrylic acid aqueous solution is (0.5~0.8):1; the volume ratio of isopropanol described in step 2③ to deionized water in the PB dispersion is (6~10):1; the molar ratio of CuCl2·2H2O described in step 2③ to polyacrylic acid in the polyacrylic acid aqueous solution is (30~35):1; the molar ratio of CuCl2·2H2O described in step 2③ to 2-methylimidazole in the 2-methylimidazole aqueous solution is 1:(5~10).

5. The method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 1, characterized in that In step 2③, a 5M ammonia solution is used to adjust the pH to 7.8-8.0; in step 2③, isopropanol and CuCl2·2H2O are added dropwise and the mixture is stirred for reaction at room temperature and a rotation speed of 500rpm-800rpm for 2h-2.5h; in step 2③, a 2-methylimidazole aqueous solution is added and the mixture is stirred for reaction at room temperature and a rotation speed of 1200rpm-1500rpm for 15min-25min.

6. The method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 1, characterized in that The mass ratio of the precipitate B described in step 2③ to the volume of deionized water is 1 mg: (5-6) mL; the mass ratio of the precipitate C described in step 2③ to the volume of deionized water is 1 mg: (6-7) mL.

7. The method for preparing a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 1, characterized in that The vacuum freeze drying described in step 2 (3) is specifically drying at a temperature of -25°C to -30°C for 1 to 2 days.

8. The use of a Janus nano drug carrier for enhancing the generation of active oxygen as prepared in claim 1, characterized in that It is used for chemodynamic therapy, photothermal therapy and drug loading; the drug is an antibacterial drug or an anticancer drug.

9. The use of a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 8, characterized in that The drug is berberine.

10. The use of a Janus nano drug carrier for enhancing the generation of active oxygen according to claim 8, characterized in that The drug loading is specifically carried out according to the following steps: dissolving the Janus nano drug carrier that enhances the generation of active oxygen in deionized water, then adding the drug, stirring for 20h to 24h at a temperature of 75°C to 80°C, a stirring speed of 800rp to 1000rpm and protected from light, then centrifuging and centrifugal washing in sequence to obtain a precipitate, dispersing the precipitate in deionized water, and finally vacuum freeze-drying to obtain drug-loaded @PBCM; the mass ratio of the Janus nano drug carrier that enhances the generation of active oxygen to the drug is 1:(1 to 2).